Mersana Therapeutics, Inc. announced the appointment of Brian C. DeSchuytner as Senior Vice President of Finance and Product Strategy, effective July 10, 2019. Mr. DeSchuytner is an accomplished life science professional with nearly two decades of experience spanning corporate strategy, finance, product development, and commercial launch. Mersana also announced the resignation of David A. Spellman as Chief Financial Officer effective as of June 30, 2019, who has decided to pursue other opportunities.

Mr. DeSchuytner joins Mersana from TESARO, where he was Vice President responsible for the ZEJULA® (niraparib) commercialization. Previously, he was Vice President responsible for the NINLARO® (ixazomib) global launch at Takeda Oncology.